Drugs / Bupropion
Bupropion
also known as
bupropion SR · Zyban · Bupropion HCl · Bupropion Hydrochloride · bupropion XL · Wellbutrin · Wellbutrin XL · BUP · +24 more
Small molecule targets TNF
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Mysimba | — | 2015-03-26 | europa.eu ↗ |
| Label expansion | US (FDA) | APLENZIN | — | 2012-08-15 | fda.gov ↗ |
| Label expansion | US (FDA) | WELLBUTRIN XL | — | 2006-06-12 | fda.gov ↗ |
| Label expansion | US (FDA) | WELLBUTRIN SR | — | 2001-06-11 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | ZYBAN | — | 1999-09-10 – 2001-02-07 | fda.gov ↗ |
| Approved | US (FDA) | WELLBUTRIN | — | 1985-12-30 | fda.gov ↗ |
Trials 265 · started per year
today
US approved 1985
EU approved 2015
1
2
4
4
2
7
7
11
25
18
7
14
6
5
2
1
6
12
12
8
11
13
4
10
16
14
5
7
8
14
9
19851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT04553263 | Jun 2023 → Jan 2025 | attention deficit-hyperactivity disorder, cognitive disorder, substance abuse | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 0 | NCT03623711 | Aug 2018 → Dec 2022 | major depressive disorder | Yuqi Cheng | Unknown | No outcome recorded |
| Phase 0 | NCT03420469 | Jun 2018 → May 2019 | thyroid hormone metabolism, abnormal | Indiana University | Completed | No outcome recorded |
| Phase 0 | NCT02582008 | Jan 2016 → Oct 2018 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, nasopharyngeal carcinoma, oral cavity squamous cell carcinoma +1 | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 0 | NCT01739192 | Jan 2013 → Dec 2017 | cocaine dependence | Craig Rush | Completed | No outcome recorded |
| Phase 163 trials | ||||||
| Phase 1 | NCT07224087 | Sep 2026 → Dec 2027 expected | obesity disorder | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07584434 | May 2026 → Mar 2027 expected | narcolepsy 1 | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
| Phase 1 | NCT07269873 | Mar → Dec 2026 expected | — | BioCorRx Pharmaceuticals Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT07223671 | Dec 2025 → Feb 2026 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT07259330 | Oct 2025 → Mar 2026 | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT07235748 | Oct → Dec 2025 | — | Servier | Completed | No outcome recorded |
| Phase 1 | NCT06930872 | Jun → Oct 2025 | — | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06973005 | May → Jul 2025 | liver disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06679413 | Dec 2024 → Jun 2025 | — | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06564441 | Oct 2024 → Dec 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06374290 | Jul → Dec 2024 | — | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 1 | NCT06367153 | May → Aug 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05932277 | Jun → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05981365 | Apr → Oct 2023 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05334108 | Apr → Aug 2022 | — | Emalex Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04899674 | Jun → Sep 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04814498 | May → Sep 2021 | — | Blade Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04464577 | Apr → Jun 2021 | — | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT04764851 | Feb → Apr 2021 | — | Emalex Biosciences Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04757532 | Dec 2020 → Mar 2021 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT04457180 | Nov 2020 → May 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04643249 | Nov → Dec 2020 | mitochondrial disease | Abliva AB | Completed | No outcome recorded |
| Phase 1 | NCT04526210 | Oct 2020 → May 2021 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04664725 | Jun 2020 → Jan 2021 | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04709094 | Jul → Oct 2019 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03864042 | Jan 2018 → Jul 2022 | cancer, metastatic melanoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03301207 | Oct 2017 → Jul 2018 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03058419 | Mar → May 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03234699 | Feb → Jul 2017 | — | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02698553 | May → Jun 2016 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02735603 | Apr → Jul 2016 | early repolarization associated with ventricular fibrillation | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02745912 | Apr → Jun 2016 | — | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02568176 | Oct 2015 → Feb 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02473627 | May → Jul 2015 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02369172 | Feb → Apr 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02305901 | Dec 2014 → Mar 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02391688 | Nov 2014 → Apr 2015 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT02048917 | Jul 2014 → May 2019 | head and neck cancer, lung cancer | University of Kentucky | Completed | No outcome recorded |
| Phase 1 | NCT02085967 | Feb → Apr 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01769768 | Apr 2013 → Aug 2016 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01771874 | Jan → May 2013 | substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01731067 | Nov 2012 → May 2013 | — | Jules Desmeules | Completed | No outcome recorded |
| Phase 1 | NCT01635972 | Jun → Jul 2012 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00625859 | Jan → Apr 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00504413 | Jul 2007 → Jan 2011 | substance-related disorder | University of Washington | Unknown | No outcome recorded |
| Phase 1 | NCT00439868 | Feb → Jun 2007 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00616915 | Jan 2007 → Jan 2009 | mood disorder | Queen's University | Completed | No outcome recorded |
| Phase 1 | NCT00865111 | Mar → Apr 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864981 | Sep → Oct 2005 | depressive disorder | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00133757 | Jun 2005 → May 2006 | nicotine dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 1 | NCT00865371 | Sep 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865410 | Aug → Sep 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865462 | Jul 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00863941 | Jun → Jul 2004 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00861939 | Mar → Apr 2004 | depressive disorder | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT03920319 | Jan 2004 → Dec 2005 | nicotine dependence | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT00136747 | Jan 2004 → May 2009 | nicotine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT00069459 | Sep 2003 → Jun 2004 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00108173 | Oct 2002 → Apr 2007 | nicotine dependence | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 1 | NCT00040040 | Jun 2002 → Sep 2003 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
| Phase 1 | NCT00018187 | Nov 1998 → Jun 2001 | — | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 1 | NCT00883155 | Oct 1998 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00000276 | Sep 1994 → Aug 1999 | cocaine abuse | Yale University | Terminated | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT07398404 | Sep 2026 → Dec 2030 expected | obesity disorder | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07596212 | Jul 2026 → Jul 2028 expected | hormone receptor-positive breast cancer, hypoactive sexual desire disorder | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06609343 | Jun → Nov 2026 expected | end stage renal failure | The University of Texas Health Science Center at San Antonio | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05976646 | Sep 2023 → Jul 2025 | opiate dependence | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT01982643 | Nov 2013 → Feb 2015 | methamphetamine dependence | Walter Ling | Completed | No outcome recorded |
| Phase 1/2 | NCT01857596 | Apr 2013 → Oct 2014 | hypoactive sexual desire disorder | S1 Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01219673 | Mar 2013 → Jan 2014 | head and neck cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01032018 | Jan 2010 → Jan 2012 | acute coronary syndrome, depressive disorder | Columbia University | Completed | No outcome recorded |
| Phase 1/2 | NCT00129246 | Dec 2004 → Dec 2005 | nicotine dependence | Yale University | Completed | No outcome recorded |
| Phase 1/2 | NCT00593099 | Apr 2004 → Jun 2006 | bipolar disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 235 trials | ||||||
| Phase 2 | NCT07523048 | Nov 2025 → Jul 2026 overdue | major depressive disorder | Roger McIntyre | Recruiting | No outcome recorded |
| Phase 2 | NCT07171112 | Nov 2025 → Jul 2026 | acute pancreatitis, chronic pancreatitis, nicotine dependence, recurrent acute pancreatitis | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 2 | NCT06517797 | Oct 2025 → Jun 2027 expected | obesity disorder | S1 Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03326128 | Sep 2021 → Jul 2023 | nicotine dependence | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT04971291 | Apr → Jul 2021 | major depressive disorder | Axsome Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04634071 | Jan 2021 → Jan 2026 | cancer-related condition | Joseph Valentino, MD | Completed | No outcome recorded |
| Phase 2 | NCT04437485 | Oct 2020 → Aug 2022 | dysthymic disorder, major depressive disorder, prediabetes syndrome, type 2 diabetes mellitus | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT04634669 | Sep 2020 → Feb 2022 | major depressive disorder | Axsome Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04167306 | Mar 2019 → Dec 2022 | alcohol dependence | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 2 | NCT02501265 | Jun 2017 → Jul 2020 | nicotine dependence | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT03180294 | May 2017 → Feb 2021 | breast carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus cancer +2 | NRG Oncology | Completed | No outcome recorded |
| Phase 2 | NCT02842073 | Nov 2016 → Dec 2017 | alcohol-related disorders | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02458690 | Jul 2015 → Aug 2019 | coronary artery disorder, dysthymic disorder, major depressive disorder, stroke disorder | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT01806779 | Mar 2013 → Dec 2014 | nicotine dependence | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01286402 | Apr 2011 → Oct 2012 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT00994448 | Oct 2009 → Dec 2011 | amphetamine abuse | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00711477 | Sep 2008 → Jun 2010 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00742573 | Aug 2008 → Jan 2014 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00624858 | Jan 2008 → Jul 2009 | depressive disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00563563 | Oct 2007 → Sep 2008 | nicotine dependence, obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00580853 | Apr 2007 → Oct 2016 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00330616 | May 2006 → Nov 2007 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00534001 | Jan 2006 → May 2008 | cervical cancer, esophageal cancer, gastric cancer, head and neck cancer +7 | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00364871 | Apr 2005 → Mar 2007 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00135512 | Dec 2004 → May 2007 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00330187 | Mar 2004 → Jul 2009 | nicotine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00218231 | Jan 2004 → Aug 2006 | nicotine dependence, schizophrenia | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00086411 | Sep 2003 → Apr 2008 | nicotine dependence | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00136760 | Sep 2003 → Mar 2009 | nicotine dependence, schizophrenia | Brown University | Completed | No outcome recorded |
| Phase 2 | NCT00069251 | Jul 2003 → Jun 2005 | methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT01875172 | Oct 2001 → Jan 2004 | pregnancy disorder | Watching Over Mothers & Babies Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00124683 | Sep 2001 → May 2007 | nicotine dependence, schizophrenia | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00227812 | Apr 2001 → Dec 2005 | cocaine dependence, major depressive disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00249509 | Sep 2000 → Sep 2004 | hallucinogen abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00001483 | Jun 1995 → May 2002 | bipolar disorder, depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2/315 trials | ||||||
| Phase 2/3 | NCT04605081 | Jan 2022 → May 2027 expected | eating disorder, obesity disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04662801 | Aug 2021 → Sep 2022 | obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT04599478 | Jun 2021 → Dec 2025 overdue | eating disorder, obesity disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04747314 | Mar 2021 → Nov 2024 | anxiety, chronic pain syndrome | Ajay Wasan, MD, Msc | Completed | No outcome recorded |
| Phase 2/3 | NCT04501016 | Sep 2020 → Aug 2021 overdue | nicotine dependence | Iowa City Veterans Affairs Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03946111 | Aug 2019 → Dec 2024 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT03539900 | Apr 2018 → Apr 2022 | binge eating disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT03047005 | Aug 2017 → Dec 2021 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT03045341 | Feb 2017 → Jul 2021 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT00621517 | Feb 2008 → Jul 2009 | restless legs syndrome | East Tennessee State University | Completed | No outcome recorded |
| Phase 2/3 | NCT00419731 | Nov 2006 → Feb 2010 | nicotine dependence | University of Minnesota | Unknown | No outcome recorded |
| Phase 2/3 | NCT00507728 | Dec 2005 → Dec 2019 | nicotine dependence | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00414167 | Dec 2005 → Mar 2011 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT00126373 | May 2005 → Mar 2006 | Crohn disease | Altschuler, Eric, M.D. | Completed | No outcome recorded |
| Phase 2/3 | NCT00080158 | Mar 2004 → Jun 2007 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 340 trials | ||||||
| Phase 3 | NCT05603104 | Apr 2025 → Jun 2028 expected | bipolar depression, major depressive disorder, schizophrenia | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT06958692 | Apr 2025 → Sep 2026 expected | major depressive disorder | CSPC Ouyi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05973786 | Feb 2025 → Jun 2028 expected | bipolar depression | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT06233799 | Jul 2024 → Oct 2026 expected | amphetamine abuse, methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05646862 | Jun 2023 → Nov 2026 expected | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05157698 | Jan 2022 → Jan 2027 expected | obesity disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05205811 | Dec 2021 → Jun 2025 | — | Rose Research Center, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04947553 | Jun 2021 → Dec 2024 | Alzheimer disease | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03342027 | Aug 2020 → Jul 2023 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 3 | NCT04388319 | May 2020 → Jun 2021 | — | Rose Research Center, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04039022 | Jul 2019 → Oct 2020 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03996265 | Jun 2019 → May 2026 overdue | cancer, hematopoietic and lymphoid system neoplasm | University of Rochester NCORP Research Base | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04019704 | Jun → Nov 2019 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03897439 | May 2019 → Nov 2021 | — | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03078075 | May 2017 → Jul 2019 | methamphetamine dependence | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02191397 | Feb 2015 → Oct 2016 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01764386 | Feb 2013 → Sep 2014 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01601704 | Jun 2012 → Aug 2015 | obesity disorder | Orexigen Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00567255 | Dec 2007 → Jun 2009 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00532779 | Oct 2007 → May 2009 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00587769 | Jul 2007 → Jul 2008 | nicotine dependence | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00474630 | May 2007 → Jun 2009 | obesity disorder, type 2 diabetes mellitus | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00456521 | Mar 2007 → Dec 2008 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00296517 | Jan 2006 → Mar 2008 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00296933 | Dec 2005 → ? | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00125957 | Aug 2005 → Jan 2010 | major depressive disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00304707 | Apr 2005 → Feb 2010 | alcohol-related disorders | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 3 | NCT00179244 | Jul 2004 → Apr 2005 | major depressive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 3 | NCT00093288 | Jun 2004 → Oct 2005 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00108537 | Oct 2003 → Sep 2005 | nicotine dependence | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 3 | NCT00414180 | Aug 2003 → May 2005 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00064467 | Jun 2003 → May 2005 | epilepsy, major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00051272 | Jan 2003 → Jun 2004 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00051259 | Jan 2003 → Jun 2004 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00048360 | Oct 2002 → Jun 2003 | attention deficit-hyperactivity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00046241 | Sep 2002 → Jun 2003 | seasonal affective disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00033592 | Feb 2002 → Jul 2006 | lung cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00086385 | Sep 2001 → Mar 2009 | nicotine dependence | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00344695 | ? → Apr 2003 | nicotine dependence | University of Arizona | Completed | No outcome recorded |
| Phase 472 trials | ||||||
| Phase 4 | NCT02129751 | Jun 2026 → Jul 2029 expected | major depressive disorder | Bausch Health Americas, Inc. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07213466 | Jan 2026 → Feb 2028 expected | bipolar I disorder, bipolar II disorder, obesity disorder, schizoaffective disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06620562 | Jun 2025 → Jun 2028 expected | morbid obesity | Laval University | Recruiting | No outcome recorded |
| Phase 4 | NCT06854614 | Mar 2025 → Apr 2027 expected | obesity disorder | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06605703 | Sep 2024 → Feb 2026 | obesity disorder | WW International Inc | Completed | No outcome recorded |
| Phase 4 | NCT06809166 | Jul 2024 → Jan 2026 overdue | obesity disorder | The Royal's Institute of Mental Health Research | Recruiting | No outcome recorded |
| Phase 4 | NCT06254001 | Jan 2024 → Jan 2025 | nicotine dependence, substance withdrawal syndrome | National Institute of Respiratory Diseases, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT05919797 | Jun 2023 → Jun 2027 expected | obesity disorder | Columbia University | Recruiting | No outcome recorded |
| Phase 4 | NCT05351606 | May 2023 → Jan 2025 | nicotine dependence | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT05537584 | Sep 2022 → Aug 2025 | major depressive disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05277207 | May 2022 → Sep 2023 | nicotine dependence | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT04587843 | Apr 2021 → Dec 2023 | obesity disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 4 | NCT04589130 | Feb 2021 → Dec 2023 | obesity disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 4 | NCT04352101 | Sep 2020 → Jul 2022 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04604509 | Aug 2020 → Dec 2028 expected | — | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04490057 | Jul 2020 → Oct 2024 | nicotine dependence | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT04098874 | Jan 2020 → Jul 2026 overdue | — | University of Minnesota | Recruiting | No outcome recorded |
| Phase 4 | NCT04135937 | Nov 2019 → Jul 2021 | HIV infectious disease | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT05531591 | Aug 2019 → Jul 2024 | cognitive impairment with or without cerebellar ataxia, dementia, major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 4 | NCT03993457 | Jul 2019 → Mar 2022 | depressive disorder | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT03219008 | Aug 2017 → Dec 2019 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT03148509 | Jun 2017 → Dec 2019 | — | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02960763 | Feb 2017 → Sep 2020 | major depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02736474 | May 2016 → Jul 2018 | obesity disorder, schizophrenia | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT02238977 | Mar 2016 → Mar 2018 | end stage renal failure, major depressive disorder | University of Arkansas | Terminated | No outcome recorded |
| Phase 4 | NCT02616315 | Feb 2016 → Oct 2017 | — | Takeda | Withdrawn | No outcome recorded |
| Phase 4 | NCT02638129 | Jan → Jun 2016 | cardiovascular disorder, obesity disorder | Orexigen Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 4 | NCT02291666 | Apr 2015 → Jul 2019 | type 2 diabetes mellitus | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT02209597 | Jun 2014 → Aug 2016 | major depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02173886 | Jun 2014 → Feb 2015 | — | North Dakota State University | Completed | No outcome recorded |
| Phase 4 | NCT01583023 | Apr 2014 → Apr 2015 | bipolar disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 4 | NCT02676375 | Jan 2014 → Jun 2016 | schizophrenia | Brentwood Biomedical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01916824 | Aug 2013 → Dec 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02401256 | Jul 2013 → May 2016 | — | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT02162862 | Jul 2013 → Jun 2016 | inflammatory bowel disease, sleep disorder | Eva Szigethy | Completed | No outcome recorded |
| Phase 4 | NCT01716221 | Oct 2012 → Mar 2013 | Friedreich ataxia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT01574703 | May 2012 → Jul 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01477931 | Nov 2010 → Jul 2011 | major depressive disorder | Chi-Un Pae | Completed | No outcome recorded |
| Phase 4 | NCT00962988 | Dec 2009 → Apr 2015 | cerebrovascular disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01015170 | Oct 2009 → Oct 2015 | nicotine dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 4 | NCT00991081 | Jul 2009 → Mar 2011 | — | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01541475 | Mar 2009 → Jan 2011 | major depressive disorder | Ewha Womans University | Completed | No outcome recorded |
| Phase 4 | NCT00846339 | Nov 2008 → Mar 2009 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00666978 | Dec 2007 → Jun 2010 | cervical cancer, esophageal cancer, gastric cancer, head and neck cancer +7 | Lisa Sanderson Cox, PhD | Completed | No outcome recorded |
| Phase 4 | NCT03927950 | Jan 2007 → Jan 2008 | major depressive disorder | University of Tartu | Completed | No outcome recorded |
| Phase 4 | NCT00404755 | Jul 2006 → Aug 2011 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00320697 | Apr 2006 → Oct 2008 | schizoaffective disorder, schizophrenia | North Suffolk Mental Health Association | Completed | No outcome recorded |
| Phase 4 | NCT01576640 | Dec 2005 → Oct 2007 | nicotine dependence, schizophrenia | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00611975 | Oct 2005 → May 2008 | — | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT00770666 | Sep 2005 → Dec 2007 | — | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT00234195 | Sep 2005 → Jan 2007 | breast cancer, major depressive disorder | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT00484692 | Jul 2005 → Jan 2007 | nicotine dependence, substance abuse | Medical University Innsbruck | Completed | No outcome recorded |
| Phase 4 | NCT00119210 | Mar 2005 → Mar 2006 | nicotine dependence | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00296712 | Feb 2005 → Jul 2006 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00181896 | Jan 2005 → Feb 2007 | bipolar disorder, depressive disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00296777 | Dec 2004 → May 2007 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00225251 | Nov 2004 → May 2008 | dysthymic disorder | St. Luke's-Roosevelt Hospital Center | Completed | No outcome recorded |
| Phase 4 | NCT00332644 | Sep 2004 → Aug 2010 | nicotine dependence | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT00316160 | Sep 2004 → May 2005 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00456820 | Jul 2004 → Nov 2007 | depressive disorder, sexual disorder | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00186446 | Jun 2004 → Sep 2007 | major depressive disorder, nicotine dependence | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00106197 | Jun 2004 → Mar 2014 | depressive disorder | Uma Rao | Unknown | No outcome recorded |
| Phase 4 | NCT00178828 | Oct 2002 → Apr 2013 | depressive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00044434 | May 2002 → Apr 2005 | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 4 | NCT00177567 | Jul 2001 → Jan 2004 | bipolar disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00021528 | Jul 2001 → Sep 2006 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00320723 | Jul 2001 → Dec 2005 | schizoaffective disorder, schizophrenia | North Suffolk Mental Health Association | Completed | No outcome recorded |
| Phase 4 | NCT00006170 | Sep 2000 → Dec 2009 | nicotine dependence | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00181818 | Oct 1999 → Dec 2003 | intermediate coronary syndrome, myocardial infarction | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00322205 | Jun 1999 → Mar 2002 | — | National Institutes of Health (NIH) | Completed | No outcome recorded |
| Phase 4 | NCT00142831 | Apr 1999 → Aug 2006 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 4 | NCT00307203 | Aug 1998 → Feb 2004 | nicotine dependence, schizophrenia | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT07654179 | Jun 2026 → Jun 2027 expected | depressive disorder, obesity disorder | Riphah International University | Recruiting | No outcome recorded |
| — | NCT06957223 | May → Nov 2025 | major depressive disorder | Asad Ullah Jan | Completed | No outcome recorded |
| — | NCT04694846 | Aug 2020 → Aug 2024 | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Thomas Jefferson University | Completed | No outcome recorded |
| — | NCT04478526 | Apr 2020 → May 2021 | generalized anxiety disorder | Dr. Nazanin Alavi | Completed | No outcome recorded |
| — | NCT04848246 | Nov 2017 → Sep 2019 | pulmonary tuberculosis | Dow University of Health Sciences | Completed | No outcome recorded |
| — | NCT03581630 | Jul 2017 → Jul 2018 | breast cancer, obesity disorder | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT02994082 | Dec 2016 → Sep 2019 | nicotine dependence | Mark Vander Weg | Unknown | No outcome recorded |
| — | NCT03553173 | Oct 2016 → Oct 2018 | — | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| — | NCT02789527 | Nov 2015 → Apr 2017 | — | Estella S. Poloni | Completed | No outcome recorded |
| — | NCT02317744 | Dec 2014 → Sep 2016 | binge eating disorder | Yale University | Completed | No outcome recorded |
| — | NCT02438072 | Dec 2014 → Dec 2015 | depressive disorder | University Hospital, Geneva | Unknown | No outcome recorded |
| — | NCT02146911 | May 2014 → Dec 2016 | nicotine dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT02104128 | Jan 2014 → May 2016 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| — | NCT01993017 | Nov 2013 → Jul 2018 | acute coronary syndrome, depressive disorder | Columbia University | Completed | No outcome recorded |
| — | NCT03563287 | Jan 2012 → Dec 2014 | morbid obesity | University of Eastern Finland | Completed | No outcome recorded |
| — | NCT00531518 | Oct 2007 → May 2013 | bipolar disorder, depressive disorder, schizophrenia | MaineHealth | Completed | No outcome recorded |
| — | NCT00572234 | Aug 2007 → Apr 2010 | methamphetamine dependence | University of Nebraska | Completed | No outcome recorded |
| — | NCT00236288 | Oct 2005 → Apr 2007 | — | Indiana University | Completed | No outcome recorded |
| — | NCT00285155 | Nov 2004 → Feb 2006 | — | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT00267813 | Jul 2004 → Oct 2007 | nicotine dependence | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT00079469 | Feb → Aug 2004 | cancer of unknown primary site | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| — | NCT00125905 | Oct 2003 → Jul 2006 | — | Jordi Gol Institute for Primary Care Research | Unknown | No outcome recorded |
| — | NCT01270555 | May 1999 → Jul 2001 | attention deficit-hyperactivity disorder, substance-related disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00012558 | Sep 1998 → Sep 2005 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| — | NCT00000268 | May 1995 → Nov 1998 | cocaine abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 127 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00625131 Comparator | May 2008 → Mar 2013 | nicotine dependence, post-traumatic stress disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT05160090 Comparator | Jan → Feb 2020 | — | Alembic Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03199339 Comparator | Aug 2017 → Jul 2018 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 1 | NCT01359930 Comparator | Aug 2011 → Jun 2012 | methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT01046214 Comparator | Jan 2010 → ? | depressive disorder | Teva Pharmaceuticals USA | Terminated | No outcome recorded |
| Phase 1 | NCT00692510 Background | Nov 2007 → Sep 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00205946 Comparator | Apr 2005 → Jul 2007 | major depressive disorder | Affective Neuroscience Laboratory | Completed | No outcome recorded |
| Phase 1 | NCT00285584 Comparator | Sep 2002 → Mar 2004 | HIV infectious disease, depressive disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00612807 Background | Jul 2006 → Jun 2010 | major depressive disorder | Duke University | Completed | No outcome recorded |
| Phase 1/2 | NCT01048983 Comparator | — | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 222 trials | ||||||
| Phase 2 | NCT05420350 Comparator | Dec 2020 → Jul 2024 | Meniere disease | Dent Neuroscience Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT04035603 Background | Oct 2020 → Jan 2021 | — | Boston University Charles River Campus | Withdrawn | No outcome recorded |
| Phase 2 | NCT04422652 Comparator | Sep 2020 → Apr 2027 expected | end stage renal failure, major depressive disorder | Stony Brook University | Recruiting | No outcome recorded |
| Phase 2 | NCT03595579 Comparator | May 2018 → Jan 2019 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03471767 Comparator | Mar 2018 → Mar 2019 | nicotine dependence | James Davis | Completed | No outcome recorded |
| Phase 2 | NCT03169244 Comparator | Sep 2017 → Aug 2019 | alcohol abuse | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT03132571 Background | Jun 2017 → Jul 2018 | obesity disorder, schizophrenia, type 2 diabetes mellitus | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT02188459 Comparator | Oct 2014 → Jan 2020 | nicotine dependence | Henry Kranzler | Completed | No outcome recorded |
| Phase 2 | NCT01592695 Background | Jun 2012 → Jun 2013 | — | Iowa City Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01914965 Comparator | Jun 2012 → May 2014 | Huntington disease | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT01407094 Comparator | Jul 2011 → Apr 2016 | depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01111149 Comparator | Dec 2009 → Aug 2012 | schizophrenia | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00833443 Comparator | Jan 2009 → Dec 2012 | methamphetamine dependence, substance abuse | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00709371 Comparator | Jul 2008 → Apr 2009 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00687713 Comparator | May 2008 → May 2011 | methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00318409 Comparator | Sep 2006 → Nov 2007 | HIV infectious disease, substance abuse | San Francisco Department of Public Health | Completed | No outcome recorded |
| Phase 2 | NCT00339014 Comparator | May 2006 → Aug 2007 | obesity disorder | Orexigen Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00135785 Comparator | Oct 2005 → May 2007 | methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00142870 Comparator | Mar 2005 → May 2006 | cannabis dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00129272 Comparator | May 2004 → Jan 2011 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00087880 Comparator | Dec 2002 → Jan 2005 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000457 Comparator | Jun 1998 → Apr 2002 | alcohol dependence | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT03063606 Background | Sep 2017 → Dec 2021 | binge eating disorder, obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 2/3 | NCT03226522 Comparator | Jul 2017 → Apr 2020 | Alzheimer disease | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT02111798 Comparator | Jul 2014 → May 2020 | cocaine dependence, substance abuse | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT01901848 Background | Dec 2013 → Jul 2017 | post-traumatic stress disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2/3 | NCT01560507 Comparator | May 2012 → Jul 2013 | nicotine dependence | Duke University | Terminated | No outcome recorded |
| Phase 2/3 | NCT00935818 Comparator | Sep 2009 → Apr 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT00749658 Comparator | Nov 2008 → Sep 2010 | nicotine dependence | University of Minnesota | Completed | No outcome recorded |
| Phase 2/3 | NCT00248118 Comparator | Jan 2005 → Aug 2007 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Terminated | No outcome recorded |
| Phase 2/3 | NCT00248209 Comparator | May 2004 → Apr 2007 | orgasm disorder | Segraves, R., T., M.D., Ph.D. | Completed | No outcome recorded |
| Phase 2/3 | NCT00061087 Comparator | Feb 1998 → Oct 2004 | attention deficit-hyperactivity disorder, cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT05732272 Comparator | Feb 2023 → Jan 2027 expected | — | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT03852160 Background | Dec 2019 → Jul 2021 | major depressive disorder | Janssen-Cilag International NV | Withdrawn | No outcome recorded |
| Phase 3 | NCT02741791 Comparator | Mar 2016 → Mar 2020 | major depressive disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02624102 Background | Sep 2015 → Dec 2017 | major depressive disorder | Hemanny, Curt, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT02050308 Background | May 2015 → Mar 2019 | — | Won Choi, PhD, MPH | Completed | No outcome recorded |
| Phase 3 | NCT02400346 Background | Mar 2015 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01892813 Background | Jul 2013 → Jan 2018 | nicotine dependence | Mark Vander Weg | Unknown | No outcome recorded |
| Phase 3 | NCT01838876 Background | Apr 2013 → Jul 2015 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01421342 Comparator | Dec 2012 → Aug 2015 | major depressive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT01715805 Background | Nov 2012 → Jun 2016 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01406223 Comparator | Jul 2011 → Dec 2013 | nicotine dependence | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT01303861 Comparator | Mar 2011 → Mar 2013 | nicotine dependence | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00958633 Comparator | Nov 2010 → Mar 2020 | bipolar I disorder | University of British Columbia | Terminated | No outcome recorded |
| Phase 3 | NCT01106456 Background | Sep 2010 → Jul 2014 | — | Won Choi, PhD, MPH | Completed | No outcome recorded |
| Phase 3 | NCT00943618 Comparator | May 2010 → May 2020 | — | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01047254 Comparator | Jan 2010 → Jul 2014 | — | University Hospital, Bonn | Completed | No outcome recorded |
| Phase 3 | NCT00440115 Background | Jun 2009 → Dec 2010 | — | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00894166 Comparator | May 2009 → Jul 2011 | — | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00351910 Background | May 2006 → Apr 2007 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00689611 Comparator | Dec 2005 → Jun 2010 | acute coronary syndrome, myocardial infarction | Mark Eisenberg | Completed | No outcome recorded |
| Phase 3 | NCT00261170 Comparator | Jul 2003 → Aug 2006 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00032084 Comparator | Jan 2002 → Feb 2004 | lung cancer | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT00063323 Comparator | Aug 2000 → Jul 2006 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 441 trials | ||||||
| Phase 4 | NCT06845345 Comparator | Apr 2025 → Jul 2027 expected | fibrotic liver disease, hyperlipidemia, hypertensive disorder, metabolic dysfunction-associated steatotic liver disease +2 | Carmen Dietvorst | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06098079 Comparator | Jan 2024 → Jan 2029 expected | obesity disorder | Currax Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06223880 Comparator | Dec 2023 → Mar 2026 overdue | major depressive disorder | Axsome Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT04902625 Comparator | Mar 2023 → Mar 2025 | morbid obesity | Zuyderland Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT06675851 Comparator | Dec 2022 → Dec 2026 expected | major depressive disorder | Medical University of Vienna | Recruiting | No outcome recorded |
| Phase 4 | NCT05273996 Background | Sep 2021 → Apr 2027 expected | major depressive disorder, neurotic disorder | David Steffens | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04388189 Comparator | Oct 2020 → May 2023 | major depressive disorder | Alto Neuroscience | Withdrawn | No outcome recorded |
| Phase 4 | NCT04575194 Comparator | Sep 2020 → Sep 2022 | hypertensive disorder, obesity disorder | National and Kapodistrian University of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT03978442 Background | Nov 2019 → Oct 2025 | post-traumatic stress disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT03950427 Comparator | Jul 2019 → Jul 2025 | nicotine dependence | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03126682 Comparator | Aug 2017 → May 2018 | major depressive disorder | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT02420015 Background | Mar 2017 → Jan 2019 | schizophrenia | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT03362099 Comparator | Nov 2016 → Apr 2022 | — | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02995915 Background | Nov 2016 → Mar 2020 | alcohol abuse | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT02332291 Comparator | Apr 2015 → Aug 2020 | major depressive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02245308 Background | Oct 2014 → Mar 2018 | nicotine dependence | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT02078180 Comparator | Apr 2014 → Nov 2016 | depressive disorder | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01942187 Comparator | Aug 2013 → Dec 2015 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT03278938 Comparator | Jun 2012 → Jan 2016 | depressive disorder | New York State Psychiatric Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT01764867 Comparator | Jun 2012 → Oct 2014 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT01456936 Comparator | Nov 2011 → Jan 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01390246 Comparator | Jul 2011 → Dec 2016 | nicotine dependence, pregnancy disorder | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 4 | NCT02178696 Background | Jan 2011 → Oct 2015 | depressive disorder | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01748955 Comparator | Jun 2010 → Mar 2015 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01023659 Comparator | Apr 2010 → Dec 2011 | nicotine dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 4 | NCT01330043 Background | Mar 2010 → Mar 2015 | — | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00926835 Comparator | May 2009 → May 2015 | major depressive disorder | Ministry of Health & Welfare, Korea | Terminated | No outcome recorded |
| Phase 4 | NCT00917059 Comparator | May 2009 → May 2012 | depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00936299 Comparator | Jan 2009 → May 2013 | attention deficit-hyperactivity disorder, cannabis dependence, nicotine dependence | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT00590863 Comparator | Mar 2008 → Sep 2009 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00519428 Comparator | Aug 2007 → Jul 2011 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00511134 Background | Apr 2007 → Dec 2008 | insomnia, nicotine dependence | Yale University | Terminated | No outcome recorded |
| Phase 4 | NCT00449007 Comparator | Feb 2006 → Dec 2010 | alcohol-related disorders, major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00495352 Comparator | Jan 2006 → Dec 2008 | nicotine dependence, schizophrenia | Yu-Li Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00132821 Comparator | Aug 2005 → May 2009 | nicotine dependence, sleep disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 4 | NCT01048944 Comparator | Jun 2005 → Jan 2013 | nicotine dependence | Southern Illinois University Carbondale | Completed | No outcome recorded |
| Phase 4 | NCT00296647 Comparator | Sep 2004 → Jul 2009 | nicotine dependence | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT00429169 Comparator | Jun 2004 → Jan 2010 | major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00176449 Comparator | Apr 2001 → Dec 2005 | nicotine dependence | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT01621009 Comparator | Jan 2001 → Oct 2002 | nicotine dependence | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT01621022 Comparator | Jan 2001 → Oct 2002 | nicotine dependence | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase not applicable21 trials | ||||||
| — | NCT07714200 Background | Mar 2027 → Mar 2030 expected | nicotine dependence | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| — | NCT06894472 Background | Mar → Apr 2025 overdue | bruxism | Beni-Suef University | Not yet recruiting | No outcome recorded |
| — | NCT06566794 Comparator | Aug 2024 → Jan 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT06467474 Background | Mar 2024 → Jun 2025 overdue | major depressive disorder | Ricardo Alberto Moreno, M.D., Ph.D. | Recruiting | No outcome recorded |
| — | NCT02873754 Background | Jan → Jul 2017 | — | Duke University | Completed | No outcome recorded |
| — | NCT02869451 Background | Aug 2016 → May 2017 | cannabis dependence | Duke University | Completed | No outcome recorded |
| — | NCT03227679 Comparator | May → Oct 2016 | nicotine dependence | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT01990079 Background | Dec 2013 → Aug 2015 | post-traumatic stress disorder | Duke University | Completed | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded |
| — | NCT01965405 Background | Aug 2013 → Dec 2021 | AIDS, nicotine dependence | Wayne State University | Unknown | No outcome recorded |
| — | NCT01896349 Background | Apr 2013 → Aug 2014 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| — | NCT01789710 Background | Jan 2013 → Sep 2014 | — | Duke University | Completed | No outcome recorded |
| — | NCT01488266 Comparator | Nov 2011 → Jan 2013 | major depressive disorder | Korea University | Unknown | No outcome recorded |
| — | NCT02744417 Background | Aug 2010 → Feb 2014 | chronic periodontitis | Claudio Mendes Pannuti | Completed | No outcome recorded |
| — | NCT00819078 Comparator | Jan 2009 → Jan 2011 | — | Geha Mental Health Center | Unknown | No outcome recorded |
| — | NCT00564278 Background | Feb 2008 → Aug 2013 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT00396669 Background | Jul 2007 → Jul 2012 | nicotine dependence | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT00817011 Comparator | Apr 2006 → Dec 2016 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00308763 Comparator | Jan 2004 → Dec 2008 | nicotine dependence | University of Tennessee | Completed | No outcome recorded |
| — | NCT00055393 Comparator | Jul 2002 → May 2005 | pathological gambling | University of Iowa | Completed | No outcome recorded |
| — | NCT00104598 Comparator | Sep 2000 → Sep 2004 | nicotine dependence | Yale University | Completed | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-10-21 | Takeda | Takeda and Orexigen Announce Availability of CONTRAVE ® (naltrexone HCl and bupropion HCl) Extended-Release Tablets for Chronic Weight Management in Obese Adults takeda.com ↗ |
| 2014-09-11 | Takeda | Takeda and Orexigen Announce FDA Approval of Contrave ® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management takeda.com ↗ |
| 2008-05-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Wellbutrin Xl® Tablets, 150 Mg tevapharm.com ↗ |
| 2007-03-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Agreement With Biovail And Anchen Regarding Generic Wellbutrin XL® tevapharm.com ↗ |
| 2006-12-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch Of Generic Wellbutrin Xl® Tablets, 300 Mg Under Agreement With Anchen And IMPAX tevapharm.com ↗ |
| 2004-05-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Commences Commercial Launch of Generic Zyban® tevapharm.com ↗ |
| 2004-03-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Commences Commercial Launch Of Bupropion 150 Mg tevapharm.com ↗ |
| 2003-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Signs Agreement With Andrx and Impax for Generic Formulations of Wellbutrin® Sr and Zyban® tevapharm.com ↗ |
Evidence & citations 37 cited values
Every value below carries the sentence it was read from. 403 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bupropion | “we randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive...” PMID 16554525 ↗ Mar 2006372“If the patient has been deemed unresponsive to both an SSRI and an SNRI/pregabalin, the patient will commence the secondary medication arm. The two classes of medications...” NCT04478526 ↗ “Nirogacestat 100 mg BID will be administered orally from Day 1 through Day 17 and an oral dose of CYP cocktail (CYP2B6 [bupropion 20 mg], CYP2C8 [repaglinide 0.05 mg], CYP2C9...” NCT07259330 ↗ “Patients will receive ECT treatment as usual, but for this study if they choose to participate they will be randomized to receive bupropion (sustained release preparation 300...” NCT03126682 ↗ “Two equally loaded capsules containing: Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone...” NCT03563287 ↗ “In this DDI part, each subject (n=14) will be administered midazolam (2 mg suspension) and bupropion (150 mg, tablet) together on Day 1, followed by a 7-day washout, followed...” NCT03199339 ↗ “we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗ “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Ten volunteers received an oral cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6),...” PMID 24722393 ↗ Apr 2014 “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “Patients with a DSM-5 diagnosis of MDD were randomized in a 1:1 ratio to receive dextromethorphan-bupropion (45 mg-105 mg tablet) or placebo, orally (once daily for days 1-3,...” PMID 35649167 ↗ May 2022 “Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion)...” NCT04662801 ↗ “An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR) in Combination With Bupropion Sustained Release (SR) in Overweight and Obese,...” NCT00563563 ↗ “Participants in group C will receive health educational mailings and an offer for free nicotine replacement therapy (six weeks) or bupropion (seven weeks) every 6 months...” NCT00440115 ↗ “Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573 ↗ “We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss.” NCT04437485 ↗ “Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily).” NCT04501016 ↗ “CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic.” NCT06809166 ↗ “ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805 ↗ “alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg” NCT02178696 ↗ “Adaptive participants who did not decrease daily cigarettes smoked by at least 50% (nonresponders) received bupropion in addition to their chosen medication.” PMID 37682573 ↗ Sep 2023 “ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)” NCT06930872 ↗ “Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose).” NCT00248209 ↗ “Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)” NCT03063606 ↗ “Participants will take Mysimba twice daily at a total dose of 32 mg/360 mg naltrexone/bupropion per day for a duration of six months.” NCT06845345 ↗ “The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine.” PMID 32851583 ↗ Nov 2020 “Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally.” NCT04587843 ↗ “Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally.” NCT04589130 ↗ “Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.” NCT02624102 ↗ “comparative efficacy of bupropion (Wellbutrin), sertraline (Zoloft), and venlafaxine (Effexor), three newer antidepressants” NCT00001483 ↗ “Clinical Evaluation of Bupropion SR (323U66)in Patients With Depression - Investigation in Elderly Patients With Depression” NCT00330616 ↗ “single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion” NCT02473627 ↗ “Participants were randomized to receive placebo (n=4454) or naltrexone, 32 mg/d, and bupropion, 360 mg/d (n=4456).” PMID 26954408 ↗ Mar 2016 “Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity).” NCT05976646 ↗ “All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)” NCT01106456 ↗ “AD: aripiprazole, bupropion, duloxetine, escitalopram, mirtazapine, sertraline, venlafaxine” NCT04747314 ↗ “Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.” NCT05277207 ↗ “In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on.” NCT06467474 ↗ “Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)” NCT01764386 ↗ “The antidepressant Bupropion is a dopamine and norepinephrine reuptake inhibitor.” NCT01047254 ↗ “Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day” NCT07654179 ↗ “Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion” NCT04035603 ↗ “Participants with the A2 allele (CC) were assigned to receive bupropion” NCT00991081 ↗ “S1B-509 (proprietary combination of trazodone and bupropion) low dose” NCT06517797 ↗ “Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks” NCT00142831 ↗ “a 12-week supply of bupropion or varenicline.” NCT00962988 ↗ “bupropion_amfebutamone, Wellbutrin, Zyban” NCT00817011 ↗ “45 mg dextromethorphan-105 mg bupropion” NCT04971291 ↗ “bupropion (Wellbutrin and others)” NCT01944657 ↗ “bupropion HCL (brand name Zyban)” NCT00322205 ↗ “- bupropion: 100mg oral tablet” NCT04764851 ↗ “bupropion: 100mg oral tablet” NCT05334108 ↗ “Bupropion (20 mg, N06AX12)” NCT02438072 ↗ “100 mg bupropion (CYP2B6)” PMID 31099895 ↗ Jul 2019 “CYP2B6 Bupropion 20 mg” NCT04814498 ↗ “Bupropion, Wellbutrin” NCT01916824 ↗ “Bupropion” NCT00863941 ↗ “Bupropion” NCT03553173 ↗ |
| Known as | 323U66 | “Clinical Evaluation of Bupropion SR (323U66)in Patients With Depression - Investigation in Elderly Patients With Depression” NCT00330616 ↗1“323U66 (Bupropion Hydrochloride Sustained Release)” NCT00296517 ↗ |
| Known as | amfebutamone | “bupropion_amfebutamone, Wellbutrin, Zyban” NCT00817011 ↗ |
| Known as | BRP | “once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)” PMID 30724759 ↗ Sep 2019 |
| Known as | BUP | “The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping...” NCT00124683 ↗6“A randomized, double-blind, parallel-group double-dummy study evaluated two medications, bupropion (BUP) and naltrexone (NTX), in treatment-seeking cigarette smokers” PMID 27213949 ↗ Jun 2016 “sustained release (SR) Bupropion (BUP) and immediate release (IR) Dextromethorphan (DXM)” NCT03471767 ↗ “initially treated with a combination of escitalopram (ESC) plus bupropion (BUP)” PMID 19820552 ↗ Sep 2009 “A combination of bupropion (BUP) and naltrexone (NTX) is effective for obesity.” NCT01739192 ↗ “bupropion (BUP), a nonserotonergic antidepressant” NCT01407094 ↗ “bupropion SR (BUP)” NCT01048944 ↗ |
| Known as | bup-SR | “In phase two, participants are offered an 8-week course of bupropion-sustained release (BUP-SR).” NCT02162862 ↗ |
| Known as | BUP-XL | “Participants will begin the 12 week medication phase of the trial. Participants will be randomized to either the 1) AMC arm and receive injections of extended release...” NCT03078075 ↗1“extended release bupropion (BUP-XL) tablets (BUP-XL)” NCT06233799 ↗ |
| Known as | bupropion extended release | “Patients (N = 245) meeting criteria for major depressive disorder (MDD), diagnosed with DSM-IV-TR, were randomly assigned to double-blind treatment with bupropion...” PMID 25295437 ↗ Sep 20142“bupropion extended release (Wellbutrin XL)” NCT00234195 ↗ “Drug: Bupropion extended release” NCT01477931 ↗ |
| Known as | Bupropion HCI | “The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.” NCT00861939 ↗2“WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline” NCT06675851 ↗ “Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.” NCT00864981 ↗ |
| Known as | Bupropion HCl | “Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week,...” NCT03581630 ↗9“The drug being tested in this study is naltrexone HCl and bupropion HCl Extended- Release fixed dose combination (NB) .” NCT02745912 ↗ “Use of smoking cessation pharmacotherapy such as Zyban (bupropion HCl) has been shown to double quit rates” NCT01015170 ↗ “Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets” NCT02616315 ↗ “Bupropion HCl 300mg Extended Release Tablet” NCT00861939 ↗ “Bupropion HCl 100 mg Tablets (Invamed Inc.)” NCT00883155 ↗ “bupropion HCL (brand name Zyban)” NCT00322205 ↗ “Bupropion HCl XL tablet 300mg” NCT02698553 ↗ |
| Known as | bupropion hydrobromide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02129751 ↗ |
| Known as | Bupropion Hydrochloride | “Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).” NCT04526210 ↗9“The purpose of the study is to evaluate the effects of a single-dose of Wellbutrin XL (bupropion hydrochloride) on reward processing.” NCT00205946 ↗ “Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers” NCT02698553 ↗ “The drug being tested in this study is called naltrexone hydrochloride/bupropion hydrochloride (NB).” NCT02616315 ↗ “Drug: bupropion hydrochloride” NCT00033592 ↗ |
| Known as | Bupropion hydrochloride (HCl) | “Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week,...” NCT03581630 ↗ |
| Known as | Bupropion Hydrochloride ER | “Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)” NCT06098079 ↗ |
| Known as | Bupropion Hydrochloride Extended-release | “A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of...” NCT00316160 ↗3“The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with...” NCT01477931 ↗ “Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks” NCT06609343 ↗ “Drug: Bupropion Hydrochloride Extended-release” NCT07398404 ↗ |
| Known as | Bupropion Hydrochloride Sustained Release | “323U66 (Bupropion Hydrochloride Sustained Release)” NCT00296517 ↗ |
| Known as | bupropion SR | “A randomized, double-blind, parallel group design will be used to allow a rigorous preliminary assessment of the feasibility, effectiveness, and safety of bupropion SR...” NCT01286402 ↗11“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour...” NCT03471767 ↗ “bupropion SR (sustained-release) are non nicotine pharmacotherapies FDA-indicated for the treatment of tobacco dependence in cigarette smokers.” NCT00935818 ↗ “Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release).” NCT02162862 ↗ “combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo” PMID 23408728 ↗ May 2013 “naltrexone sustained-release (SR, 32 mg/day), combined with bupropion SR (360 mg/day) plus BMOD” PMID 20559296 ↗ Jun 2010 “Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)” NCT01764386 ↗ “Naltrexone SR 32 mg/bupropion SR 360 mg/ day” NCT00474630 ↗ “100mg of Bupropion SR in the morning” NCT00296517 ↗ “Bupropion SR 150 mg tablet” NCT01390246 ↗ “bupropion SR (BUP)” NCT01048944 ↗ |
| Known as | bupropion XL | “Mothers of healthy infants who quit smoking while pregnant will be stratified based on current or past history of major depressive disorder or persistent depressive disorder...” PMID 33706003 ↗ Mar 20218“In this double-blind, multicenter study, bupropion XL, a norepinephrine-dopamine reuptake inhibitor, and venlafaxine XR, a serotonin-norepinephrine reuptake inhibitor, were...” PMID 16974189 ↗ Oct 2006 “Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose).” NCT00248209 ↗ “Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers” NCT02698553 ↗ “Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services.” NCT02842073 ↗ “extended-release bupropion (bupropion XL)” PMID 16848645 ↗ Jun 2006 “bupropion XL” NCT01488266 ↗ |
| Known as | Bupropion, Wellbutrin | “bupropion = Wellbutrin” NCT00296712 ↗1“Bupropion, Wellbutrin” NCT01916824 ↗ |
| Known as | bupropion-Sustained Release | “Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release).” NCT02162862 ↗ |
| Known as | buproprion | “Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway.” NCT00001483 ↗ |
| Known as | Elontril | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04899674 ↗ |
| Known as | Pharmacotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06894472 ↗ |
| Known as | Welbutrin XL | “once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)” PMID 30724759 ↗ Sep 2019 |
| Known as | Wellbutrin | “Patients will receive ECT treatment as usual, but for this study if they choose to participate they will be randomized to receive bupropion (sustained release preparation 300...” NCT03126682 ↗8“Bupropion (a medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers.” NCT00129272 ↗ “the sustained release (SR) and extended release (XL) medication bupropion (Wellbutrin®)” NCT02173886 ↗ “Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).” NCT04490057 ↗ “Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway.” NCT00001483 ↗ “bupropion_amfebutamone, Wellbutrin, Zyban” NCT00817011 ↗ “time-released bupropion (Wellbutrin)” NCT00044434 ↗ “bupropion (Wellbutrin and others)” NCT01944657 ↗ |
| Known as | WELLBUTRIN SR | “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗4“The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®).” NCT00178828 ↗ “Sustained release (SR) bupropion (Zyban, Wellbutrin SR) is a non-nicotine antidepressant drug” NCT00181818 ↗ “WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline” NCT06675851 ↗ “WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline” NCT00864981 ↗ |
| Known as | Wellbutrin XL | “A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of...” NCT00316160 ↗7“WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.” NCT00439868 ↗ “bupropion extended-release tablets (BRP; as Wellbutrin XL®)” NCT01982643 ↗ “bupropion extended release (Wellbutrin XL)” NCT00234195 ↗ “Bupropion: Wellbutrin XL®” NCT03078075 ↗ |
| Known as | Wellbutrin, bupropion | “Wellbutrin, bupropion” NCT00126373 ↗ |
| Known as | Zyban | “The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping...” NCT00124683 ↗11“The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®).” NCT00178828 ↗ “This is an open label study, wherein eligible participants will be randomized to receive bupropion (Zyban®) or varenicline (Champix®) for 12 weeks” NCT02146911 ↗ “We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban).” NCT00267813 ↗ “Bupropion (a medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers.” NCT00129272 ↗ “Sustained release (SR) bupropion (Zyban, Wellbutrin SR) is a non-nicotine antidepressant drug” NCT00181818 ↗ “Bupropion SR 150mg tabs (Zyban) twice daily” NCT00994448 ↗ “bupropion_amfebutamone, Wellbutrin, Zyban” NCT00817011 ↗ “bupropion HCL (brand name Zyban)” NCT00322205 ↗ |
| Known as | Zyban SR | “Bupropion's (Zyban(®) SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, placebo-controlled study with chronic, heavy marihuana users.” PMID 22879754 ↗ Jun 20121“Bupropion (Zyban SR)” NCT00063323 ↗ |
| Known as | Zyban Sustained Release | “Bupropion (brand name Zyban Sustained Release).” NCT00063323 ↗ |
| Known as | Zyban(R) | “sustained-release bupropion (Zyban(R))” NCT00484692 ↗ |
| Known as | Zyntabac | “Usual pharmacological therapy consists of bupropion (Zyntabac 150 mg) or varenicline (Champix 0.5 mg or 1 mg).” PMID 30522992 ↗ Dec 2018 |
| Action | Inhibit | “The antidepressant Bupropion is a dopamine and norepinephrine reuptake inhibitor.” NCT01047254 ↗ |
| Modality | Small molecule | “Bupropion, an amphetamine derivative” NCT00133757 ↗ |
| Route | Oral | “Patients receive oral bupropion once daily on days 1-3 and twice daily on days 4-77.” NCT00032084 ↗ |
| Target | TNF | “The investigators will also be looking to see if Wellbutrin can lower levels of the inflammatory cytokine tumor necrosis factor-alpha (TNF).” NCT00126373 ↗ |